<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10093936</article-id><article-id pub-id-type="pmcid-ver">PMC10093936.1</article-id><article-id pub-id-type="pmcaid">10093936</article-id><article-id pub-id-type="pmcaiid">10093936</article-id><article-id pub-id-type="pmid">37047257</article-id><article-id pub-id-type="doi">10.3390/ijms24076286</article-id><article-id pub-id-type="publisher-id">ijms-24-06286</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Biomarkers of Exposure and Potential Harm in Two Weeks of Smoking Abstinence: Changes in Biomarkers of Platelet Function, Oxidative Stress, and Inflammation</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7199-0628</contrib-id><name name-style="western"><surname>Makena</surname><given-names initials="P">Patrudu</given-names></name><xref rid="af1-ijms-24-06286" ref-type="aff">1</xref><xref rid="c1-ijms-24-06286" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Scott</surname><given-names initials="E">Eric</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="af1-ijms-24-06286" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="P">Peter</given-names></name><xref rid="af1-ijms-24-06286" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="HP">Hsiao-Pin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-ijms-24-06286" ref-type="aff">1</xref><xref rid="fn1-ijms-24-06286" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="BA">Bobbette A.</given-names></name><xref rid="af1-ijms-24-06286" ref-type="aff">1</xref><xref rid="fn1-ijms-24-06286" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prasad</surname><given-names initials="GL">Gaddamanugu L.</given-names></name><xref rid="af1-ijms-24-06286" ref-type="aff">1</xref><xref rid="af2-ijms-24-06286" ref-type="aff">2</xref><xref rid="fn1-ijms-24-06286" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Catani</surname><given-names initials="MV">Maria Valeria</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Gasperi</surname><given-names initials="V">Valeria</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Savini</surname><given-names initials="I">Isabella</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-06286"><label>1</label>RAI Services Company, 401 N. Main Street, Winston-Salem, NC 27101, USA</aff><aff id="af2-ijms-24-06286"><label>2</label>Prasad Scientific Consulting LLC, Lewisville, NC 27023, USA</aff><author-notes><corresp id="c1-ijms-24-06286"><label>*</label>Correspondence: <email>makenap@rjrt.com</email></corresp><fn id="fn1-ijms-24-06286"><label>&#8224;</label><p>Former employees of RAIS, 401 N. Main Street, Winston-Salem, NC 27101, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>24</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">433371</issue-id><elocation-id>6286</elocation-id><history><date date-type="received"><day>01</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>19</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-14 16:10:31.860"><day>14</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-24-06286.pdf"/><abstract><p>Chronic cigarette smoking is a major risk factor for many serious diseases. While complete cessation of smoking is the best option to reduce harm from smoking, adverse impacts of smoking on health could persist for several years after cessation. Therefore, Biomarkers of Potential Harm (BoPH) are useful in interim evaluations of the beneficial effects of smoking cessation or switching to potentially lower-risk tobacco products. A 14-day smoking abstinence study was conducted under clinical confinement conditions and enrolled 70 subjects into younger (24&#8211;34 years, <italic toggle="yes">n</italic> = 33) and older (35&#8211;60 years, <italic toggle="yes">n</italic> = 37) age cohorts. Biomarkers of Exposure (BoE), which indicate exposure to nicotine and other toxicants, were measured at baseline, 7 and 14 days. Several BoPH including previously identified eicosanoids (leukotriene 4 (LTE4) and 2,3-dinor thromboxane <sub>2</sub> (2,3-d-TXB<sub>2</sub>) and others were evaluated. Significant declines in BoE, LTE<sub>4,</sub> 2,3-d-TXB<sub>2</sub>, neutrophils, WBC and select RBC, and arterial blood gas parameters were observed in both age cohorts at Days 7 and 14 compared to baseline, while other BoPH (e.g., FeNO) showed age-related effects. Rapid and reproducible reductions in LTE<sub>4</sub>, 2,3-d-TXB<sub>2</sub> WBC, and neutrophil counts were consistently detected following smoking abstinence, indicating the value of these markers as useful BoPH.</p></abstract><kwd-group><kwd>smoking abstinence</kwd><kwd>biomarkers of potential harm</kwd><kwd>biomarkers of exposure</kwd><kwd>2,3-d-TXB<sub>2</sub></kwd><kwd>LTE<sub>4</sub></kwd><kwd>neutrophils</kwd><kwd>WBC</kwd></kwd-group><funding-group><award-group><funding-source>RAIS</funding-source></award-group><funding-statement>This study was funded by RAIS, a subsidiary of Reynolds American Inc. RAI Services Company is a wholly owned subsidiary of Reynolds American Inc., which is a wholly owned subsidiary of British American Tobacco plc.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-06286"><title>1. Introduction</title><p>Cigarette smoking is a major risk factor for cardiovascular diseases (CVD), cancer, and chronic obstructive pulmonary disease (COPD), which typically develop over several years of sustained smoking [<xref rid="B1-ijms-24-06286" ref-type="bibr">1</xref>]. Combustion-related toxicants in cigarette smoke cause oxidative stress and chronic inflammation, among other perturbations, which lead to smoking-related diseases in susceptible smokers. Smoking cessation is the best option for smokers to reduce the risk of developing smoking-related diseases [<xref rid="B2-ijms-24-06286" ref-type="bibr">2</xref>].</p><p>The Family Smoking Prevention and Tobacco Control Act authorized the Food and Drug Administration (FDA) to regulate the marketing of tobacco products in USA [<xref rid="B3-ijms-24-06286" ref-type="bibr">3</xref>]. Premarket and modified risk tobacco product authorizations are two such mechanisms of regulation under the tobacco control act [<xref rid="B3-ijms-24-06286" ref-type="bibr">3</xref>]. The FDA established several Harmful and Potential Harmful Constituents (HPHCs) in cigarette smoke and identified them as causative toxicants of smoking-related diseases [<xref rid="B4-ijms-24-06286" ref-type="bibr">4</xref>]. Biomarkers are useful tools to assess exposure to HPHCs and the biological effects from tobacco exposure [<xref rid="B5-ijms-24-06286" ref-type="bibr">5</xref>].</p><p>In the context of tobacco use-related health effects, Biomarkers of Exposure (BoE) and Biomarkers of Potential Harm (BoPH) have been broadly recognized [<xref rid="B5-ijms-24-06286" ref-type="bibr">5</xref>,<xref rid="B6-ijms-24-06286" ref-type="bibr">6</xref>,<xref rid="B7-ijms-24-06286" ref-type="bibr">7</xref>]. BoE quantify exposure to the HPHCs, whereas BoPH inform of the effects of exposure to toxicants. Biomarkers of exposure include nicotine, carbon monoxide and tobacco-specific nitrosamines (NNAL, NNN, NAT, and NAB). Exposure to nicotine is measured as a composite of nicotine and five other metabolites and expressed as total nicotine equivalents. Changes in smoking related BoPH precede the manifestation of the disease. The BoPH are distinct from surrogate biomarkers [<xref rid="B8-ijms-24-06286" ref-type="bibr">8</xref>]. BoPH could serve as intermediate endpoints for assessing potential health risks of tobacco use as well as determining how soon physiological functions may improve following smoking cessation [<xref rid="B6-ijms-24-06286" ref-type="bibr">6</xref>].</p><p>Cigarette smoking impacts multiple organ systems and diverse cell types [<xref rid="B1-ijms-24-06286" ref-type="bibr">1</xref>]. For example, smoking-induced oxidative stress activates platelets and renders them prothrombotic. Hyperactive platelets are important mediators of smoking-induced cardiovascular outcomes [<xref rid="B1-ijms-24-06286" ref-type="bibr">1</xref>]. Arachidonic acid metabolites, play an important role in platelet activation and atherothrombosis [<xref rid="B9-ijms-24-06286" ref-type="bibr">9</xref>]. It is well established that smokers have elevated levels of thromboxane A<sub>2</sub> metabolites including 11-dehydro-thromboxane B<sub>2</sub> (11-dh-TXB<sub>2</sub>) and 2, 3, dinor thromboxane B<sub>2</sub> (2,3-d-TXB<sub>2</sub>), which are widely recognized markers of platelet activation [<xref rid="B10-ijms-24-06286" ref-type="bibr">10</xref>,<xref rid="B11-ijms-24-06286" ref-type="bibr">11</xref>]. For example, we and others have shown in cross-sectional studies that thromboxane metabolites and other arachidonic acid (AA) metabolite levels are higher in generally healthy smokers [<xref rid="B12-ijms-24-06286" ref-type="bibr">12</xref>,<xref rid="B13-ijms-24-06286" ref-type="bibr">13</xref>,<xref rid="B14-ijms-24-06286" ref-type="bibr">14</xref>]. Further, platelet activation markers have been reported to decrease following smoking cessation, and only two weeks of smoking cessation was reported to improve platelet aggregability [<xref rid="B15-ijms-24-06286" ref-type="bibr">15</xref>,<xref rid="B16-ijms-24-06286" ref-type="bibr">16</xref>]. Thus, changes in the levels of platelet activation markers could inform of the early biological effects of cigarette smoking or cessation and serve as BoPH.</p><p>Other commonly employed BoPH encompass biochemical (e.g., isoprostane F2), cellular (e.g., white blood cell counts [WBC]), and physiological (e.g., forced expiratory volume in one second [FEV1]) markers, among other categories [<xref rid="B6-ijms-24-06286" ref-type="bibr">6</xref>,<xref rid="B17-ijms-24-06286" ref-type="bibr">17</xref>,<xref rid="B18-ijms-24-06286" ref-type="bibr">18</xref>]. Some important attributes of BoPH are their relation to a disease pathway and its responsiveness to smoking cessation. Chronic cigarette smoking profoundly alters human biology [<xref rid="B1-ijms-24-06286" ref-type="bibr">1</xref>] and many of those effects are not readily reversed with smoking cessation. For example, FEV1, a key measure of lung function, requires relatively sustained smoking cessation of several months to years to observe a significant improvement [<xref rid="B19-ijms-24-06286" ref-type="bibr">19</xref>,<xref rid="B20-ijms-24-06286" ref-type="bibr">20</xref>].</p><p>In an effort to identify BoPH that rapidly respond to smoking cessation and are mechanistically linked to the development of smoking-related diseases, RAI Services Company (RAIS) has identified two urinary eicosanoids, leukotriene E<sub>4</sub> (LTE<sub>4</sub>) and 2,3-d-TXB<sub>2</sub> [<xref rid="B14-ijms-24-06286" ref-type="bibr">14</xref>], and shown that the levels of eicosanoids rapidly decline upon smoking cessation or switching to non-combustible tobacco products [<xref rid="B21-ijms-24-06286" ref-type="bibr">21</xref>,<xref rid="B22-ijms-24-06286" ref-type="bibr">22</xref>]. With an objective to further qualify LTE<sub>4</sub> and 2,3-d-TXB<sub>2</sub>, we conducted a two-week biomarker study under clinical confinement, which we refer to as the Smoking Abstinence (SAB) study. Given that age and duration of chronic smoking could impact BoPH differentially, we assessed the effect of smokers&#8217; age on biomarker changes upon smoking abstinence by recruiting study participants into two broad age groups. We also measured changes in select BoE to assess declines in exposure to HPHCs following smoking cessation. Further, we explored the effect of two-week smoking cessation on several other cellular (hematological) and physiological BoPH.</p></sec><sec sec-type="results" id="sec2-ijms-24-06286"><title>2. Results</title><p>In order to assess biochemical and cellular changes following smoking abstinence and identify potential BoPH that could be utilized for regulatory purposes, we conducted a clinical study, in which smokers were confined to residential conditions for 14 days. <xref rid="ijms-24-06286-f001" ref-type="fig">Figure 1</xref> summarizes the study design for the SAB clinical study, in which adult smokers abstained from smoking and nicotine-containing products for 14 days in a confinement setting. The SAB was a single-center, two-cohort smoking abstinence study, in which generally healthy adult male and female smokers participated (<xref rid="ijms-24-06286-t001" ref-type="table">Table 1</xref>). Smokers of 10&#8211;20 cigarettes per day for at least five years prior to screening were recruited. Seventy subjects (51 males and 19 females) were enrolled into the study, 33 subjects in the 24&#8211;34 age cohort and 37 in the 35&#8211;60 age cohort. Sixty-eight subjects completed the study and two subjects discontinued early. Additional details of the study conduct are detailed in the <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Section</xref>.</p><sec id="sec2dot1-ijms-24-06286"><title>2.1. Urinary Biomarkers of Exposure</title><p>We measured exposure to several representative HPHCs at baseline and following smoking abstinence for 7 and 14 days. Bioanalytical methods for urinary BoE are summarized in <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S1</xref>. Declines in BoE upon smoking abstinence were in alignment with the respective reported half-lives, and profound reductions were observed in all urinary BoE on Days 7 and 14 (<xref rid="ijms-24-06286-t002" ref-type="table">Table 2</xref>). Total nicotine equivalents (NicEq-T), a composite measure of the excretion of nicotine plus five metabolites, declined from baseline on both Days 7 and 14 (about 98% reduction) in both age cohorts. The 2-cyanoethylmercapturic acid (CEMA), a representative BoE for volatile organic compounds [<xref rid="B7-ijms-24-06286" ref-type="bibr">7</xref>,<xref rid="B23-ijms-24-06286" ref-type="bibr">23</xref>,<xref rid="B24-ijms-24-06286" ref-type="bibr">24</xref>] markedly decreased from baseline on Day 7 (88%) and Day 14 (91%) in both age cohorts.</p><p>The urinary levels of the tobacco specific nitrosamines (TSNAs) also rapidly declined, reflective of their half-lives. Reductions in NNAL-T (a biomarker for NNK exposure) levels were 71% and 83% on Days 7 and 14, respectively, for both age cohorts. NNN-T levels decreased rapidly in both age cohorts on Days 7 and 14, with a 99% change from the baseline values. Similarly, notable declines in NAB-T and NAT-T levels were observed for both age cohorts on both days.</p></sec><sec id="sec2dot2-ijms-24-06286"><title>2.2. Blood Biomarkers of Exposure</title><p>Bioanalytical methods for measuring blood BoE are summarized in <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S1</xref>. Blood BoE results for plasma nicotine, plasma cotinine, and carboxyhemoglobin (COHb) were significantly lower on Day 7 and Day 14 for both age cohorts (<xref rid="ijms-24-06286-t002" ref-type="table">Table 2</xref>). The levels of plasma nicotine and cotinine demonstrated a 98% reduction in nicotine levels for both age cohorts on Days 7 and 14. Mean Blood COHb levels for both age cohorts were approximately 60% lower on Days 7 and 14 relatives to baseline values.</p></sec><sec id="sec2dot3-ijms-24-06286"><title>2.3. Biomarkers of Potential Harm</title><p>Previous work has established that smoking abstinence and/or exclusive switching to non-combustible tobacco products, such as moist snuff and ENDS (i.e., Vuse ENDS), resulted in significant declines (24&#8211;43%) in the BoPH LTE<sub>4</sub> and 2,3-d-TXB<sub>2</sub> levels within 5 days of product switching [<xref rid="B22-ijms-24-06286" ref-type="bibr">22</xref>]. In this study, we determined whether continued smoking abstinence would further lower these BoPH and if age would impact them. Bioanalytical methods for measuring BoPH are summarized in <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S2</xref>. Urinary 2,3-d-TXB<sub>2</sub> levels 7 days after abstinence decreased by approximately 47% and 28% for the younger and older age cohorts, respectively (<xref rid="ijms-24-06286-f002" ref-type="fig">Figure 2</xref>A and <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S3</xref>). Continued abstinence for 14 days sustained the decrease in 2,3-d-TXB<sub>2</sub> to about 40% for both cohorts, suggesting a reversal of platelet activation (<xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S3</xref>).</p><p>Urinary levels of LTE<sub>4</sub> were also reduced after 7 days of smoking abstinence by approximately 42% and 26% compared to baseline for the younger and older cohorts, respectively (<xref rid="ijms-24-06286-f002" ref-type="fig">Figure 2</xref>B; <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S3</xref>). Similar reductions were also observed at 14 days, where LTE<sub>4</sub> levels decreased approximately 36% and 31% in the younger and older cohorts, respectively. Reduction in LTE<sub>4</sub> levels suggest a reduced state airway hypersensitivity. While additional statistically significant differences in the mean differences from baseline were found for other BoPH tested, they were not consistent. For example, mean differences for 8-iso-PGF2&#945; from baseline were statistically significantly lower only for the younger cohort, representing a 36% and 29% reduction on Days 7 and 14, respectively (<xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S3</xref>). Other BoPH changes were also not significant and not consistent.</p></sec><sec id="sec2dot4-ijms-24-06286"><title>2.4. Hematological Biomarkers</title><p>Cigarette smoking is associated with chronic inflammation, as evident from elevated WBC and leukocyte subtypes [<xref rid="B25-ijms-24-06286" ref-type="bibr">25</xref>], which is a common feature of smoking-related diseases [<xref rid="B1-ijms-24-06286" ref-type="bibr">1</xref>]. To assess which of the cell types rapidly reverses following smoking abstinence, CBC with differential data was analyzed at baseline and at 7 and 14 days following smoking abstinence (<xref rid="ijms-24-06286-t003" ref-type="table">Table 3</xref>, <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S4</xref>). By Day 7, the WBC count decreased by 13% and 25% in the younger and older age cohorts, respectively. The declines in WBC counts appear to be rapid, as the Day 14 counts (11% and 21% in the younger and older age cohorts, respectively) were comparable to those at Day 7 of abstinence. Among the major subpopulations of WBC, neutrophil counts were significantly lower after 7 days (18% and 31% decline) and 14 days (17% and 28% decline) of abstinence in both the younger and older age cohorts, respectively, with the neutrophil counts in the older cohort demonstrating larger percent declines compared to the younger cohort. Lymphocyte counts, while lower in both age cohorts, only reached statistical significance in the older age cohort at Day 7 (16%) and Day 14 (11%). Thus, smoking abstinence leads to a rapid decrease in WBC, driven by changes in neutrophil counts, and those declines were steeper in the older age cohort.</p><p>Additionally, smoking also results in increases in red blood cell (RBC) counts and other hematological parameters [<xref rid="B25-ijms-24-06286" ref-type="bibr">25</xref>]. Smoking abstinence for 7 days resulted in decreased levels of RBC (2% and 3%), hematocrit (2% and 3%), and hemoglobin (3% and 3%) in the younger and older age cohorts, respectively (<xref rid="ijms-24-06286-t003" ref-type="table">Table 3</xref>). At 14 days of abstinence, further declines in RBC counts, hematocrit, and hemoglobin (4% for all parameters) were observed in both age cohorts were observed.</p></sec><sec id="sec2dot5-ijms-24-06286"><title>2.5. Physiological Biomarkers of Potential Harm</title><p>Long-term cigarette smoking alters pulmonary ventilation, which leads to impaired gas exchange and consequently a decline in lung function. We assessed arterial blood gas (ABG) parameters as a measure of lung function at baseline and 14 days of smoking abstinence (<xref rid="ijms-24-06286-t004" ref-type="table">Table 4</xref>). Statistically significant changes in the mean differences from baseline for each cohort were found in several of the ABG indices on Day 14 relative to baseline values. For the older cohort, the mean difference of the partial pressure of oxygen on Day 14 from baseline was statistically significant, representing a 4% increase from baseline. The partial pressure of CO<sub>2</sub> means differences from baseline on Day 14 for the younger cohort and the older cohort increased 3% and 5% from baseline, respectively. The bicarbonate mean differences from baseline on Day 14 for the younger and older cohorts increased 3% and 4% from baseline, respectively. The percent oxygen saturation mean difference from baseline on Day 14 for the older cohort was 1% higher than baseline. Overall, the older age group showed improvement compared to the younger age group. However, for FeNO, a marked increase from baseline was observed for only the younger cohort (reflecting a 56% improvement) on Day 14.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-24-06286"><title>3. Discussion</title><p>One criterion for the selection of a smoking related BoPH is that the biomarker must be responsive to changes in smoking status. In efforts to identify and qualify BoPH, we evaluated several biomarkers in a 14-day smoking abstinence study. We found that smoking abstinence rapidly restores the levels of select biomarkers of risk to a normal state (i.e., levels comparable to those of non-smokers). We demonstrated that LTE4 (a marker of airway hypersensitivity) and 2,3-d-TXB2 (a marker of platelet aggregation) rapidly declined in generally healthy smokers in response to smoking abstinence.</p><p>Several studies have shown that BoE are significantly higher in smokers and decline rapidly upon smoking cessation or with use of noncombustible tobacco products [<xref rid="B26-ijms-24-06286" ref-type="bibr">26</xref>,<xref rid="B27-ijms-24-06286" ref-type="bibr">27</xref>,<xref rid="B28-ijms-24-06286" ref-type="bibr">28</xref>,<xref rid="B29-ijms-24-06286" ref-type="bibr">29</xref>]. Although the levels of BoPH differ between asymptomatic smokers, few studies have examined how rapidly these levels decline with smoking cessation. For example, cigarette smoking is known to cause oxidative stress and induce chronic inflammation, which are central mechanisms in the development of CVD, COPD, and cancer [<xref rid="B6-ijms-24-06286" ref-type="bibr">6</xref>]. Thus, a reduction in the BoPH indicative of oxidative stress and resolution of chronic inflammation upon cessation (or switching to alternative non-combusted tobacco products) reflects a return to normal physiology and might indicate reduced disease risk compared to continued smoking. Therefore, we focused on a subcategory of BoPH, biomarkers of risk that rapidly respond to changes in smoking status, as potential tools for tobacco product evaluation.</p><p>The levels of some eicosanoids are known to increase in smokers, most likely due to smoking-induced oxidative stress, and their levels are reported to decrease upon smoking abstinence. Several studies have shown that smokers exhibit higher urinary levels of the AA metabolites LTE<sub>4</sub>, 8-iso PGF<sub>2&#945;</sub>, 2,3-d-TXB<sub>2</sub> and 11-dehydrothromboxane B<sub>2</sub> (11-dh-TXB<sub>2</sub>) compared to non-smokers or users of moist snuff [<xref rid="B11-ijms-24-06286" ref-type="bibr">11</xref>,<xref rid="B14-ijms-24-06286" ref-type="bibr">14</xref>,<xref rid="B30-ijms-24-06286" ref-type="bibr">30</xref>]. In the current study, significant reductions in 8-iso PGF<sub>2&#945;</sub> levels were observed in only the younger age cohort at both 7 and 14 days of smoking abstinence (36% and 29%, respectively; <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Scheme S3</xref>). A recent meta-analysis also reported higher levels of 8-iso PGF<sub>2&#945;</sub> in smokers and noted the availability of limited information on smoking cessation [<xref rid="B30-ijms-24-06286" ref-type="bibr">30</xref>]. Modest declines in 8-iso PGF<sub>2&#945;</sub> levels were also reported in a 3-month smoking cessation study with limited subjects [<xref rid="B31-ijms-24-06286" ref-type="bibr">31</xref>].</p><p>Corroborating our previously published work [<xref rid="B22-ijms-24-06286" ref-type="bibr">22</xref>], the levels of LTE<sub>4</sub> in the current study were significantly lower in both age cohorts after 7 days of smoking abstinence, and those decreases were sustained at 14 days. The percent decline in this BoPH is comparable to that observed in non-smokers and moist snuff consumers [<xref rid="B14-ijms-24-06286" ref-type="bibr">14</xref>], suggesting that near-maximal reductions could be achieved within a week and are sustained further in smoking abstinence.</p><p>Cigarette smoking is a major risk factor for CVD, and smokers exhibit elevated levels of thromboxane A2 (TXA<sub>2</sub>), which promotes platelet activation, a key event in the development of CVD [<xref rid="B32-ijms-24-06286" ref-type="bibr">32</xref>,<xref rid="B33-ijms-24-06286" ref-type="bibr">33</xref>]. The short-lived TXA<sub>2</sub> is metabolized to 2,3-d-TXB<sub>2</sub> and 11-dh-TXB<sub>2</sub>, which are routinely measured in urine as measures of platelet activation. The declines in 2,3-d-TXB<sub>2</sub> levels in 7 and 14 days are consistent with the findings from our previous work, which showed similar rapid declines following smoking abstinence or switching to ENDS products [<xref rid="B21-ijms-24-06286" ref-type="bibr">21</xref>,<xref rid="B22-ijms-24-06286" ref-type="bibr">22</xref>]. Several studies have reported that levels of 11-dh-TXB<sub>2</sub> are also higher in smokers compared to non-smokers (including moist snuff users) [<xref rid="B12-ijms-24-06286" ref-type="bibr">12</xref>,<xref rid="B13-ijms-24-06286" ref-type="bibr">13</xref>,<xref rid="B14-ijms-24-06286" ref-type="bibr">14</xref>]. A meta-analysis [<xref rid="B11-ijms-24-06286" ref-type="bibr">11</xref>] confirmed a higher urinary excretion of 11-dh-TXB<sub>2</sub> in smokers compared to non-smokers, and also discussed several cessation studies that reported a rapid decline in the urinary levels of 11-dh-TXB<sub>2</sub>. For example, 2,3-d-TXB<sub>2</sub> and 11-dh-TXB<sub>2</sub> declined by three days in women (<italic toggle="yes">n</italic> = 8) who quit smoking [<xref rid="B16-ijms-24-06286" ref-type="bibr">16</xref>]. While, we found reductions in 11-dh-TXB<sub>2</sub> previously, we were unable to replicate a consistent, statistically significant reversibility of urinary levels of 11-dh-TXB<sub>2</sub> following smoking abstinence in this or previous studies [<xref rid="B22-ijms-24-06286" ref-type="bibr">22</xref>].</p><p>Morita eta al [<xref rid="B15-ijms-24-06286" ref-type="bibr">15</xref>] reported that smoking cessation reduced agonist-induced platelet aggregation in 2 weeks smoking cessation, which was sustained for 4 weeks in healthy male medical students with a mean age of 27.4 years. A more recent report by Kito et al. [<xref rid="B34-ijms-24-06286" ref-type="bibr">34</xref>] indicated that platelet aggregability returns to baseline levels after 12 weeks of smoking cessation, with a transient increase at 4 and 8 weeks; this study enrolled both male and female subjects with ages ranging from 35 to 71. In our study, platelet activation was not statistically significant in both age groups at baseline, 7 and 14 days of smoking abstinence. The variance between the two studies could be due to differences in subject demographics. As discussed, the levels of 2,3-d-TXB<sub>2</sub> were significantly lower at 7 and 14 days relative to baseline.</p><p>Other BoPH that are consistently elevated in smokers include the total WBC count and its composite leukocyte subpopulations, and RBC parameters. The rapid declines we observed in WBC, neutrophil, and lymphocyte counts in smoking abstinence are consistent with the findings from a previous 2-week smoking cessation study [<xref rid="B35-ijms-24-06286" ref-type="bibr">35</xref>]. Further, short-term switching to cessation or electrically heated cigarettes also significantly lowers neutrophil count within three days [<xref rid="B36-ijms-24-06286" ref-type="bibr">36</xref>].</p><p>Chronic cigarette smoking alters pulmonary ventilation and leads to impaired gas exchange, which can be measured via ABG analysis. The impact of age on ABG parameters (PaO<sub>2</sub>, PaCO<sub>2</sub>, and O<sub>2</sub> saturation) has not previously been clearly described in smokers [<xref rid="B37-ijms-24-06286" ref-type="bibr">37</xref>]. However, in our study, markedly lower baseline values of the ABG parameters in the older cohort compared to the younger cohort indicated an impact of prolonged exposure to toxicants present in cigarette smoke (based on years of smoking [<xref rid="ijms-24-06286-t001" ref-type="table">Table 1</xref>]) and a decline in lung function. The 14 days of smoking abstinence significantly improved PaO<sub>2</sub> and O<sub>2</sub> saturation in the older age cohort.</p><p>Lower than normal levels of PaCO<sub>2</sub> at baseline in the older cohort suggest long-term smoking impacts, CO<sub>2</sub> clearance, and causes an increase in CO<sub>2</sub> loss. The decrease in PaCO<sub>2</sub> could be due to the hypoxia that is generally observed in long-term smokers, which stimulates hyperventilation in an attempt to correct hypoxia at the expense of CO<sub>2</sub> loss [<xref rid="B38-ijms-24-06286" ref-type="bibr">38</xref>]. However, this study recruited asymptomatic/generally healthy smokers, and hence the improvement in the ABG parameters is small but statistically significant.</p><p>Oxidative stress caused by cigarette smoking has been known to reduce the levels of FeNO in smokers&#8217; lungs [<xref rid="B1-ijms-24-06286" ref-type="bibr">1</xref>], and the levels of exhaled nitric oxide are reported to increase following smoking cessation [<xref rid="B39-ijms-24-06286" ref-type="bibr">39</xref>,<xref rid="B40-ijms-24-06286" ref-type="bibr">40</xref>]. In this study, we report a significant increase in FeNO on Day 14 compared to baseline only in the younger cohort. The impact of smoking on respiratory inflammation depends on cumulative pack-years and time since smoking abstinence. In addition, it is reported that age may impact FeNO levels [<xref rid="B41-ijms-24-06286" ref-type="bibr">41</xref>]. Sustained long-term smoking and age augment respiratory inflammation [<xref rid="B42-ijms-24-06286" ref-type="bibr">42</xref>]. Our data show that some biomarkers, such as FeNO, require longer than two weeks of smoking cessation in older smokers to observe a prominent change, and age may influence the rapidity of reversal of smoking-induced changes.</p><p>Among the strengths of this study, no pharmacological intervention was offered to aid with smoking abstinence, and the subjects tolerated the smoking restriction well, indicating that the clinical risk markers could be useful. Additionally, the BoPH rapidly responded to smoking abstinence in an age-dependent way and are therefore useful for product evaluation in short-term clinical studies. The WBC markers (lymphocytes and neutrophils) and RBC markers (RBC counts, hemoglobin, and hematocrit) were responsive to smoking abstinence (SAB study) in study populations ranging from 21 to 60 years. These findings demonstrate that these markers are responsive to smoking status and are not confounded by age. Since some of the favorable BoPH changes in this short-term SAB study are also replicated in longer-term ambulatory studies using ENDS or heated tobacco products [<xref rid="B43-ijms-24-06286" ref-type="bibr">43</xref>,<xref rid="B44-ijms-24-06286" ref-type="bibr">44</xref>], short-term evaluation of BoPH allows for rapid evaluation of tobacco products for regulatory purposes.</p><p>Some aberrant effects of smoking on normal biological processes persist for an extended period following smoking cessation or switching use to products with modified risk potential. Thus, the 14-day SAB study may not completely capture all changes, or some of the changes could be adaptive and might need to be stabilized. However, our previous cross-sectional study showed the levels of LTE<sub>4</sub> and 2,3-d-TXB<sub>2</sub> are about 47% higher in smokers compared to non-smokers [<xref rid="B14-ijms-24-06286" ref-type="bibr">14</xref>], which is comparable to the degree of reduction achieved in the SAB study (<xref rid="ijms-24-06286-f002" ref-type="fig">Figure 2</xref>; <xref rid="app1-ijms-24-06286" ref-type="app">Supplemental Scheme S3</xref>). This indicates that near-maximal recovery of the BoPH was achieved in two weeks in both the younger and older cohorts. Further, declines in WBC counts reported in the SAB study were also noted in longer-term ambulatory studies in which smokers were switched to heated tobacco products [<xref rid="B44-ijms-24-06286" ref-type="bibr">44</xref>]. A second limitation of the study is that due to the limited enrollment of women in the study, we were not able to assess the impact of sex as a confounding factor. However, two studies that had a more even distribution of males and females also reported reductions in WBC, neutrophils, and lymphocytes upon smoking cessation for two weeks [<xref rid="B35-ijms-24-06286" ref-type="bibr">35</xref>] or 26 weeks [<xref rid="B45-ijms-24-06286" ref-type="bibr">45</xref>], although the studies did not specifically analyze the effect of sex.</p><p>In summary, we have further characterized LTE<sub>4</sub> and 2,3-d-TXB<sub>2</sub>, neutrophils, and WBC, and have shown improvements in select RBC parameters in smoking abstinence. Hence, these BoPH are relevant early clinical markers of smoking-related diseases. Taken together with the markedly lower exposure to BoE and the improvements in BoPH, these data suggest some key biological processes start recovering quickly following a short period of smoking abstinence. Further, the BoPH are useful tools to evaluate the effects of smoking cessation and for tobacco product regulation.</p></sec><sec id="sec4-ijms-24-06286"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-24-06286"><title>4.1. Ethical Conduct</title><p>The SAB study (ClinicalTrials.gov Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04979013">NCT04979013</ext-link>) was approved by a fully accredited Institutional Review Board (Advarra; FDA/Office of Human Research Protections IRB#00000971) and was conducted under the principles of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) E6(R2). Advarra&#8217;s headquarters is at 6100 Merriweather Dr., Suite 600 Columbia, MD.</p></sec><sec id="sec4dot2-ijms-24-06286"><title>4.2. Study Design</title><p>The primary objective of the SAB study was to determine the levels of LTE<sub>4</sub> and 2,3-d-TXB<sub>2</sub> in the two age cohorts during two weeks of smoking abstinence. The rationale for biomarker selection and details of bioanalytical assays are summarized in the <xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Section</xref> (<xref rid="app1-ijms-24-06286" ref-type="app">Supplementary Schemes S1, S2 and S4</xref>). The primary study endpoints were the BoPH urinary AA metabolites 2,3-d-TXB<sub>2</sub> and LTE<sub>4</sub> in samples collected on Day &#8722;1 (baseline) and Day 14.</p></sec><sec id="sec4dot3-ijms-24-06286"><title>4.3. Statistical Analysis</title><p>All enrolled subjects were included in the descriptive summary of demographics and baseline characteristics, which are presented by age cohort. A two-sided paired t-test was used to assess the statistical significance of changes from baseline to Day 7 or Day 14. All statistical analyses were performed using SAS (100 SAS Campus Dr, Cary, NC, USA), and statistical significance was considered at <italic toggle="yes">p</italic> &#8804; 0.05. For the biomarker endpoints evaluated, only those cohort comparisons that showed at least one statistically significant result and showed consistent patterns are discussed.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors sincerely thank Celerion for collaborating and conducting the clinical study. In addition, the authors would like to thank Megan J. Whelen (RAI Services Company) for assistance with manuscript preparation and editing.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-24-06286"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms24076286/s1">https://www.mdpi.com/article/10.3390/ijms24076286/s1</uri>. References [<xref rid="B46-ijms-24-06286" ref-type="bibr">46</xref>,<xref rid="B47-ijms-24-06286" ref-type="bibr">47</xref>,<xref rid="B48-ijms-24-06286" ref-type="bibr">48</xref>,<xref rid="B49-ijms-24-06286" ref-type="bibr">49</xref>] are cited in the supplementary materials.</p><supplementary-material id="ijms-24-06286-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-24-06286-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: P.M. and G.L.P.; Methodology: P.M., G.L.P., E.S. and B.A.J. Investigation: P.M. and B.A.J.; Formal Analysis: P.M., B.A.J., P.C. and H.-P.L.; Resources: G.L.P.; Writing, review &amp; Editing: G.L.P., P.M. and B.A.J.; Supervision: P.M. and G.L.P.; Project Administration: P.M.; Funding Acquisition: G.L.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The SAB study (ClinicalTrials.gov Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04979013">NCT04979013</ext-link>) was approved by a fully accredited Institutional Review Board (Advarra; FDA/Office of Human Research Protections IRB#00000971).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author. The data are not publicly available due to proprietary reasons.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All the authors are current or former employees of RAIS. The SAB study was funded by the RAI Services Company. RAI Services Company is a wholly owned subsidiary of Reynolds American Inc., which is a wholly owned subsidiary of British American Tobacco plc. P.M., E.S., P.C. and are current full-time employees of RAIS. H.-P.L., B.A.J. and G.L.P. are former employees of RAIS. G.L.P. works as an independent scientific consultant. </p></notes><ref-list><title>References</title><ref id="B1-ijms-24-06286"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>U.S. Department of Health and Human Services</collab></person-group><article-title>How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General</article-title><source>A report of the Surgeon General</source><publisher-name>Centers for Disease Control and Prevention Office on Smoking and Health</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2010</year><pub-id pub-id-type="pmid">21452462</pub-id></element-citation></ref><ref id="B2-ijms-24-06286"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>U.S. Department of Health and Human Services</collab></person-group><source>Smoking Cessation: A Report of the Surgeon General</source><person-group person-group-type="editor"><collab>U.S. Department of Health and Human Services</collab><collab>National Center for Chronic Disease Centers for Disease Control and Prevention and Office on Smoking and Health Prevention and Health Promotion</collab></person-group><publisher-name>U.S. Department of Health and Human Services</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B3-ijms-24-06286"><label>3.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Congress</collab></person-group><source>Family Smoking Prevention and Tobacco Control and Federal Retirement Reform. Public Law 2009:111&#8211;31</source><person-group person-group-type="editor"><collab>HHS</collab></person-group><year>2009</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/tobacco-products/rules-regulations-and-guidance/family-smoking-prevention-and-tobacco-control-act-table-contents" ext-link-type="uri">https://www.fda.gov/tobacco-products/rules-regulations-and-guidance/family-smoking-prevention-and-tobacco-control-act-table-contents</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-28">(accessed on 28 February 2023)</date-in-citation></element-citation></ref><ref id="B4-ijms-24-06286"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke</source><person-group person-group-type="editor"><collab>Established List. U.S. Department of Health and Human Services</collab></person-group><publisher-name>Office of the Federal Register</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2012</year><volume>Volume 77</volume><fpage>20034</fpage><lpage>20037</lpage></element-citation></ref><ref id="B5-ijms-24-06286"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Institute of Medicine Committee to Assess the Science Base for Tobacco Harm Reduction</collab></person-group><source>Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction</source><person-group person-group-type="editor"><name name-style="western"><surname>Stratton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bondurant</surname><given-names>S.</given-names></name></person-group><publisher-name>National Academies Press (US)</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2001</year><pub-id pub-id-type="pmid">25057541</pub-id></element-citation></ref><ref id="B6-ijms-24-06286"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mishina</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Del Valle-Pinero</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>van Bemmel</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Hatsukami</surname><given-names>D.K.</given-names></name></person-group><article-title>Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop</article-title><source>Nicotine Tob. Res.</source><year>2019</year><volume>21</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntx273</pub-id><pub-id pub-id-type="pmid">29253243</pub-id></element-citation></ref><ref id="B7-ijms-24-06286"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Arab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del Valle-Pinero</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hatsukami</surname><given-names>D.K.</given-names></name></person-group><article-title>Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2017</year><volume>26</volume><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0675</pub-id><pub-id pub-id-type="pmid">28151705</pub-id><pub-id pub-id-type="pmcid">PMC5336443</pub-id></element-citation></ref><ref id="B8-ijms-24-06286"><label>8.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA-NIH Biomarker Working Group</collab></person-group><article-title>BEST (Biomarkers, EndpointS, and Other Tools) Resource</article-title><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK326791/pdf/Bookshelf_NBK326791.pdf" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK326791/pdf/Bookshelf_NBK326791.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-11-25">(accessed on 25 November 2020)</date-in-citation><pub-id pub-id-type="pmid">27010052</pub-id></element-citation></ref><ref id="B9-ijms-24-06286"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badimon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vilahur</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Patrono</surname><given-names>C.</given-names></name></person-group><article-title>The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis</article-title><source>Cardiovasc. Res.</source><year>2021</year><volume>117</volume><fpage>2001</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvab003</pub-id><pub-id pub-id-type="pmid">33484117</pub-id></element-citation></ref><ref id="B10-ijms-24-06286"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrono</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>B.</given-names></name></person-group><article-title>Measurement of Thromboxane Biosynthesis in Health and Disease</article-title><source>Front. Pharm.</source><year>2019</year><volume>10</volume><fpage>1244</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01244</pub-id><pub-id pub-id-type="pmid">31736753</pub-id><pub-id pub-id-type="pmcid">PMC6832017</pub-id></element-citation></ref><ref id="B11-ijms-24-06286"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Plas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pouly</surname><given-names>S.</given-names></name><name name-style="western"><surname>de La Bourdonnaye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>G.</given-names></name><name name-style="western"><surname>L&#252;dicke</surname><given-names>F.</given-names></name></person-group><article-title>Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B(2)</article-title><source>Toxicol. Rep.</source><year>2018</year><volume>5</volume><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2018.04.005</pub-id><pub-id pub-id-type="pmid">29854626</pub-id><pub-id pub-id-type="pmcid">PMC5977536</pub-id></element-citation></ref><ref id="B12-ijms-24-06286"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost-Pineda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rimmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roethig</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>M.</given-names></name></person-group><article-title>Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study</article-title><source>Nicotine Tob. Res.</source><year>2011</year><volume>13</volume><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntq235</pub-id><pub-id pub-id-type="pmid">21330277</pub-id></element-citation></ref><ref id="B13-ijms-24-06286"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>McEwan</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers</article-title><source>Clin. Chem. Lab. Med.</source><year>2009</year><volume>47</volume><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2009.069</pub-id><pub-id pub-id-type="pmid">19676143</pub-id></element-citation></ref><ref id="B14-ijms-24-06286"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>E.O.</given-names></name></person-group><article-title>A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers</article-title><source>Clin. Chem. Lab. Med.</source><year>2016</year><volume>54</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1515/cclm-2015-0594</pub-id><pub-id pub-id-type="pmid">26495926</pub-id></element-citation></ref><ref id="B15-ijms-24-06286"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haramaki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Imaizumi</surname><given-names>T.</given-names></name></person-group><article-title>Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers</article-title><source>J. Am. Coll. Cardiol.</source><year>2005</year><volume>45</volume><fpage>589</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.10.061</pub-id><pub-id pub-id-type="pmid">15708708</pub-id></element-citation></ref><ref id="B16-ijms-24-06286"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#229;ngemark</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ciabattoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wennmalm</surname><given-names>A.</given-names></name></person-group><article-title>Excretion of thromboxane metabolites in healthy women after cessation of smoking</article-title><source>Arterioscler. Thromb. A J. Vasc. Biol.</source><year>1993</year><volume>13</volume><fpage>777</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.13.6.777</pub-id><pub-id pub-id-type="pmid">8499397</pub-id></element-citation></ref><ref id="B17-ijms-24-06286"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Brownawell</surname><given-names>A.M.</given-names></name></person-group><source>Biological Efects Assessment in the Evaluation of Potential Reduced-Risk Tobacco Products</source><publisher-name>The Life Sciences Research Office</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2007</year><fpage>242</fpage></element-citation></ref><ref id="B18-ijms-24-06286"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatsukami</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Pentel</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Kotlyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borgida</surname><given-names>E.</given-names></name><name name-style="western"><surname>Le</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>S.S.</given-names></name></person-group><article-title>Developing the science base for reducing tobacco harm</article-title><source>Nicotine Tob. Res.</source><year>2007</year><volume>9</volume><issue>(Suppl. S4)</issue><fpage>S537</fpage><lpage>S553</lpage><pub-id pub-id-type="doi">10.1080/14622200701679040</pub-id><pub-id pub-id-type="pmid">18067031</pub-id><pub-id pub-id-type="pmcid">PMC4222243</pub-id></element-citation></ref><ref id="B19-ijms-24-06286"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohadana</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>F.</given-names></name><name name-style="western"><surname>Westin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martinet</surname><given-names>Y.</given-names></name></person-group><article-title>Smoking cessation&#8212;But not smoking reduction--improves the annual decline in FEV1 in occupationally exposed workers</article-title><source>Respir. Med.</source><year>2006</year><volume>100</volume><fpage>1423</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2005.11.005</pub-id><pub-id pub-id-type="pmid">16356702</pub-id></element-citation></ref><ref id="B20-ijms-24-06286"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pride</surname><given-names>N.B.</given-names></name></person-group><article-title>Smoking cessation: Effects on symptoms, spirometry and future trends in COPD</article-title><source>Thorax</source><year>2001</year><volume>56</volume><issue>(Suppl. S2)</issue><fpage>ii7</fpage><lpage>ii10</lpage><pub-id pub-id-type="pmid">11514700</pub-id><pub-id pub-id-type="pmcid">PMC1765983</pub-id></element-citation></ref><ref id="B21-ijms-24-06286"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanobe</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Makena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Darnell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caraway</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>G.L.</given-names></name><etal/></person-group><article-title>Part three: A randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or Abstinence</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>20658</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-25054-z</pub-id><pub-id pub-id-type="pmid">36450821</pub-id><pub-id pub-id-type="pmcid">PMC9712618</pub-id></element-citation></ref><ref id="B22-ijms-24-06286"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>G.L.</given-names></name></person-group><article-title>Urinary Leukotriene E4 and 2,3-Dinor Thromboxane B2 are Biomarkers of Potential Harm in Short-term Tobacco Switching Studies</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2019</year><volume>28</volume><fpage>2095</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-0342</pub-id><pub-id pub-id-type="pmid">31558507</pub-id></element-citation></ref><ref id="B23-ijms-24-06286"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Carmella</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wilkens</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Le Marchand</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hatsukami</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>S.S.</given-names></name></person-group><article-title>Urinary Cyanoethyl Mercapturic Acid, a Biomarker of the Smoke Toxicant Acrylonitrile, Clearly Distinguishes Smokers From Nonsmokers</article-title><source>Nicotine Tob. Res.</source><year>2020</year><volume>22</volume><fpage>1744</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntaa080</pub-id><pub-id pub-id-type="pmid">32391548</pub-id><pub-id pub-id-type="pmcid">PMC7542649</pub-id></element-citation></ref><ref id="B24-ijms-24-06286"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>F.</given-names></name><name name-style="western"><surname>Errington</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sterz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>G.</given-names></name></person-group><article-title>Urinary excretion of the acrylonitrile metabolite 2-cyanoethylmercapturic acid is correlated with a variety of biomarkers of tobacco smoke exposure and consumption</article-title><source>Biomarkers</source><year>2011</year><volume>16</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.3109/1354750X.2010.533287</pub-id><pub-id pub-id-type="pmid">21108560</pub-id><pub-id pub-id-type="pmcid">PMC3026342</pub-id></element-citation></ref><ref id="B25-ijms-24-06286"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>&#199;olak</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ellervik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hasselbalch</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Bojesen</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Nordestgaard</surname><given-names>B.G.</given-names></name></person-group><article-title>Smoking and Increased White and Red Blood Cells</article-title><source>Arter. Thromb. Vasc. Biol.</source><year>2019</year><volume>39</volume><fpage>965</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.312338</pub-id><pub-id pub-id-type="pmid">30866659</pub-id></element-citation></ref><ref id="B26-ijms-24-06286"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>N.</given-names></name><name name-style="western"><surname>McEwan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>E.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hedge</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hossack</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects</article-title><source>Nicotine Tob. Res.</source><year>2019</year><volume>21</volume><fpage>1220</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1093/ntr/nty104</pub-id><pub-id pub-id-type="pmid">29912406</pub-id><pub-id pub-id-type="pmcid">PMC6698948</pub-id></element-citation></ref><ref id="B27-ijms-24-06286"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krautter</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.X.</given-names></name><name name-style="western"><surname>Borgerding</surname><given-names>M.F.</given-names></name></person-group><article-title>Consumption patterns and biomarkers of exposure in cigarette smokers switched to Snus, various dissolvable tobacco products, Dual use, or tobacco abstinence</article-title><source>Regul. Toxicol. Pharm.</source><year>2015</year><volume>71</volume><fpage>186</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2014.12.016</pub-id><pub-id pub-id-type="pmid">25549549</pub-id></element-citation></ref><ref id="B28-ijms-24-06286"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theophilus</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Coggins</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Borgerding</surname><given-names>M.F.</given-names></name></person-group><article-title>Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: A one-week clinical confinement study</article-title><source>Regul. Toxicol. Pharm.</source><year>2015</year><volume>71</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2014.12.023</pub-id><pub-id pub-id-type="pmid">25572415</pub-id></element-citation></ref><ref id="B29-ijms-24-06286"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Bosilkovska</surname><given-names>M.</given-names></name><name name-style="western"><surname>de La Bourdonnaye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haziza</surname><given-names>C.</given-names></name></person-group><article-title>Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: A controlled, randomized, open-label 5-day exposure trial</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>19227</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-76222-y</pub-id><pub-id pub-id-type="pmid">33154508</pub-id><pub-id pub-id-type="pmcid">PMC7644773</pub-id></element-citation></ref><ref id="B30-ijms-24-06286"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Plas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pouly</surname><given-names>S.</given-names></name><name name-style="western"><surname>de La Bourdonnaye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>G.</given-names></name><name name-style="western"><surname>L&#252;dicke</surname><given-names>F.</given-names></name></person-group><article-title>Influence of smoking on levels of urinary 8-iso Prostaglandin F2&#945;</article-title><source>Toxicol. Rep.</source><year>2019</year><volume>6</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2018.11.011</pub-id><pub-id pub-id-type="pmid">30519530</pub-id><pub-id pub-id-type="pmcid">PMC6260378</pub-id></element-citation></ref><ref id="B31-ijms-24-06286"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McElroy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Carmella</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Heskin</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Reisinger</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hatsukami</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>P.G.</given-names></name></person-group><article-title>Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0218386</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0218386</pub-id><pub-id pub-id-type="pmid">31251764</pub-id><pub-id pub-id-type="pmcid">PMC6599218</pub-id></element-citation></ref><ref id="B32-ijms-24-06286"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kodali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tello-Montoliu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Angiolillo</surname><given-names>D.J.</given-names></name></person-group><article-title>Role of platelets and antiplatelet therapy in cardiovascular disease</article-title><source>J. Atheroscler. Thromb.</source><year>2011</year><volume>18</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.5551/jat.7633</pub-id><pub-id pub-id-type="pmid">21427504</pub-id></element-citation></ref><ref id="B33-ijms-24-06286"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallucci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tartarone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lerose</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lalinga</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Capobianco</surname><given-names>A.M.</given-names></name></person-group><article-title>Cardiovascular risk of smoking and benefits of smoking cessation</article-title><source>J. Thorac. Dis.</source><year>2020</year><volume>12</volume><fpage>3866</fpage><lpage>3876</lpage><pub-id pub-id-type="doi">10.21037/jtd.2020.02.47</pub-id><pub-id pub-id-type="pmid">32802468</pub-id><pub-id pub-id-type="pmcid">PMC7399440</pub-id></element-citation></ref><ref id="B34-ijms-24-06286"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Onuma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsujimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagase</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tokuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kozawa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Iida</surname><given-names>H.</given-names></name></person-group><article-title>Smoking cessation affects human platelet activation induced by collagen</article-title><source>Exp. Ther. Med.</source><year>2019</year><volume>18</volume><fpage>3809</fpage><lpage>3816</lpage><pub-id pub-id-type="doi">10.3892/etm.2019.8025</pub-id><pub-id pub-id-type="pmid">31616510</pub-id><pub-id pub-id-type="pmcid">PMC6781815</pub-id></element-citation></ref><ref id="B35-ijms-24-06286"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bain</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feher</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sever</surname><given-names>P.S.</given-names></name></person-group><article-title>Acute changes in haematological parameters on cessation of smoking</article-title><source>J. R. Soc. Med.</source><year>1992</year><volume>85</volume><fpage>80</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1177/014107689208500209</pub-id><pub-id pub-id-type="pmid">1538385</pub-id><pub-id pub-id-type="pmcid">PMC1294887</pub-id></element-citation></ref><ref id="B36-ijms-24-06286"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roethig</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Koval</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muhammad-Kah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Unverdorben</surname><given-names>M.</given-names></name></person-group><article-title>Short term effects of reduced exposure to cigarette smoke on white blood cells, platelets and red blood cells in adult cigarette smokers</article-title><source>Regul. Toxicol. Pharm.</source><year>2010</year><volume>57</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2010.04.005</pub-id><pub-id pub-id-type="pmid">20394790</pub-id></element-citation></ref><ref id="B37-ijms-24-06286"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardie</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Buist</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Ellingsen</surname><given-names>I.</given-names></name><name name-style="western"><surname>M&#248;rkve</surname><given-names>O.</given-names></name></person-group><article-title>Reference values for arterial blood gases in the elderly</article-title><source>Chest</source><year>2004</year><volume>125</volume><fpage>2053</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1378/chest.125.6.2053</pub-id><pub-id pub-id-type="pmid">15189921</pub-id></element-citation></ref><ref id="B38-ijms-24-06286"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fricker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goggins</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Mateer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R.Y.</given-names></name><name name-style="western"><surname>Gellatly</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Jarnicki</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Radford-Smith</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>3</volume><fpage>e94040</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.94040</pub-id><pub-id pub-id-type="pmid">29415878</pub-id><pub-id pub-id-type="pmcid">PMC5821186</pub-id></element-citation></ref><ref id="B39-ijms-24-06286"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;gman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holmkvist</surname><given-names>T.</given-names></name><name name-style="western"><surname>W&#229;linder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meril&#228;inen</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#250;dv&#237;ksd&#243;ttir</surname><given-names>D.</given-names></name><name name-style="western"><surname>H&#229;kansson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hedenstr&#246;m</surname><given-names>H.</given-names></name></person-group><article-title>Increased nitric oxide elimination from the airways after smoking cessation</article-title><source>Clin. Sci.</source><year>2002</year><volume>103</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1042/cs1030015</pub-id><pub-id pub-id-type="pmid">12095399</pub-id></element-citation></ref><ref id="B40-ijms-24-06286"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kharitonov</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>D.</given-names></name><name name-style="western"><surname>Keatings</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>P.J.</given-names></name></person-group><article-title>Acute and chronic effects of cigarette smoking on exhaled nitric oxide</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1995</year><volume>152</volume><fpage>609</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.152.2.7543345</pub-id><pub-id pub-id-type="pmid">7543345</pub-id></element-citation></ref><ref id="B41-ijms-24-06286"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malerba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Damiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carpagnano</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Olivini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Radaeli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ragnoli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Foschino</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>M.</given-names></name></person-group><article-title>Values in Elderly People for Exhaled Nitric Oxide Study</article-title><source>Rejuvenation Res.</source><year>2016</year><volume>19</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1089/rej.2015.1706</pub-id><pub-id pub-id-type="pmid">26414479</pub-id></element-citation></ref><ref id="B42-ijms-24-06286"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strzelak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ratajczak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adamiec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feleszko</surname><given-names>W.</given-names></name></person-group><article-title>Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review</article-title><source>Int. J. Environ. Res. Public Health</source><year>2018</year><volume>15</volume><elocation-id>1033</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph15051033</pub-id><pub-id pub-id-type="pmid">29883409</pub-id><pub-id pub-id-type="pmcid">PMC5982072</pub-id></element-citation></ref><ref id="B43-ijms-24-06286"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>M.</given-names></name></person-group><article-title>Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers</article-title><source>Nicotine Tob. Res.</source><year>2020</year><volume>22</volume><fpage>1114</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntz185</pub-id><pub-id pub-id-type="pmid">31563966</pub-id><pub-id pub-id-type="pmcid">PMC7291803</pub-id></element-citation></ref><ref id="B44-ijms-24-06286"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakaguchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takeshige</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>N.</given-names></name></person-group><article-title>Differences in Levels of Biomarkers of Potential Harm among Users of a Heat-not-burn Tobacco Product, Cigarette Smokers, and Never-Smokers in Japan: A Post-Marketing Observational Study</article-title><source>Nicotine Tob. Res.</source><year>2021</year><volume>23</volume><fpage>1143</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntab014</pub-id><pub-id pub-id-type="pmid">33502518</pub-id><pub-id pub-id-type="pmcid">PMC8274485</pub-id></element-citation></ref><ref id="B45-ijms-24-06286"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frederiksen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>R.</given-names></name></person-group><article-title>Prospective study on the effect of smoking and nicotine substitution on leucocyte blood counts and relation between blood leucocytes and lung function</article-title><source>Thorax</source><year>1998</year><volume>53</volume><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1136/thx.53.9.784</pub-id><pub-id pub-id-type="pmid">10319062</pub-id><pub-id pub-id-type="pmcid">PMC1745328</pub-id></element-citation></ref><ref id="B46-ijms-24-06286"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frans</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gerin-Portier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Veriter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brasseur</surname><given-names>L.</given-names></name></person-group><article-title>Pulmonary Gas Exchange in Asymptomatic Smokers and Nonsmokers</article-title><source>Scand. J. Respir Dis.</source><year>1975</year><volume>56</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">1209196</pub-id></element-citation></ref><ref id="B47-ijms-24-06286"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kullmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kronenberger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Siekmeier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>M.</given-names></name></person-group><article-title>The Value of Studies of Pulmonary Gas Exchange During Exercise for Evaluation of Reduced Arterial Oxygenation at Rest in Asymptomatic Long-Term Smokers</article-title><source>Pneumologie</source><year>1994</year><volume>48</volume><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">8153114</pub-id></element-citation></ref><ref id="B48-ijms-24-06286"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouattara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tuo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dah</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siransy</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Bogui</surname><given-names>P.</given-names></name></person-group><article-title>Effect of Smoking on Pao2 at Rest and During Moderate Exercise</article-title><source>Dakar Med.</source><year>2002</year><volume>47</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15776604</pub-id></element-citation></ref><ref id="B49-ijms-24-06286"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.A.</given-names></name></person-group><article-title>The Comparision of Two Exhaled Nitric Oxide Analyzers: Niox Vero and Sunvou-Ca2122</article-title><source>J. Breath Res.</source><year>2021</year><volume>15</volume><fpage>026007</fpage><pub-id pub-id-type="doi">10.1088/1752-7163/abd193</pub-id><pub-id pub-id-type="pmid">33291088</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-06286-f001" orientation="portrait"><label>Figure 1</label><caption><p>Study Design of Smoking Abstinence Study. The smoking abstinence study consisted of the 14-day clinical confinement of smokers to evaluate biomarker changes. Blood and urine samples were collected at baseline (Day -1) and Days 7 and 14 of smoking abstinence. Biomarker measurements were made at baseline after 7 days and/or 14 days of smoking abstinence, as indicated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06286-g001.jpg"/></fig><fig position="float" id="ijms-24-06286-f002" orientation="portrait"><label>Figure 2</label><caption><p>Change in leukotriene 4 (<bold>A</bold>) and 2,3-dinor-thromboxane B2 (<bold>B</bold>) levels following smoking abstinence. Leukotriene 4 (<bold>A</bold>) and 2,3-dinor-thromboxane B2 (<bold>B</bold>) levels rapidly decline following smoking abstinence. Urine samples from a 24 h period obtained at baseline Day 7 and Day 14 from smokers switched from usual brand (UB) cigarettes to smoking abstinence were used to measure leukotriene 4 (<bold>A</bold>) and 2,3-dinor-thromboxane B2 (<bold>B</bold>) by LC/MS-MS. Each individual data point represents subject-level measurements. <italic toggle="yes">p</italic> &lt; 0.01 when comparing baseline with post-switching to abstinence (Day 7 and Day 14) for both Leukotriene 4 and 2,3-dinor-thromboxane B.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06286-g002.jpg"/></fig><table-wrap position="float" id="ijms-24-06286-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06286-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographics and Subject Characteristics of Smoking Abstinence Study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age Cohort</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#8211;34<break/>(N = 33)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35&#8211;60<break/>(N = 37)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Overall<break/>(N = 70)</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sex n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (12%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (41%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (27%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (59%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 (73%)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Race n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black or African American</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (15%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (11%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (79%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (84%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57 (81%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (7%)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ethnicity n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hispanic or Latino</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not Hispanic or Latino</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (91%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 (96%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age <sup>a</sup> (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.0 (3.12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.2 (8.10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.2 (11.52)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FTND Score</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5 (1.70)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.0 (1.57)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 (1.63)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Years of Smoking <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.8 (4.08)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.3 (11.30)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.5 (11.94)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cigarettes Smoked per Day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.6 (4.48)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4 (4.02)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.5 (4.21)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cigarette Variety n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Menthol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (30%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (19%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (24%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-Menthol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (70%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (81%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53 (76%)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Age is calculated as the age at date of informed consent. <sup>b</sup> Years of Smoking is calculated as informed consent date minus smoking start date. FTND = Fagerstr&#246;m Test for Nicotine Dependence (0 = no dependency; 1 to 2 = low dependency; 3 to 4 = low to moderate dependency; 5 to 7 = moderate to high dependency; 8 to 10 = high dependency); n = number of subjects within a category; N = total number of subjects; SD = standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-06286-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06286-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of Changes in Urinary and Blood Biomarkers of Exposure on Days &#8722;1, 7, and 14 of Smoking Abstinence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Urine Biomarkers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age Cohort</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomarker (Units)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Statistics</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time Point</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#8211;34 Years</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35&#8211;60 Years</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NicEq-T (mg/24 h)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.4 &#177; 6.6 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.3 &#177; 6.4 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4 &#177; 0.2 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4 &#177; 0.1 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4 &#177; 0.3 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4 &#177; 0.2 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;97% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98% *</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CEMA (&#181;g/24 h)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">273.6 &#177; 115.1 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">240.3 &#177; 91.1 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.0 &#177; 12.8 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.1 &#177; 14.6 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.3 &#177; 9.3 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4 &#177; 13.1 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;88% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;88% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;91% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;91% *</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NNN-T (pg/24 h)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,380 &#177; 10,164 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,380 &#177; 39,703 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">240.0 &#177; 101.3 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">251.9 &#177; 80.8 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">232.9 &#177; 146.7 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">232.7 &#177; 124.6 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NAB-T (ng/24 h)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.4 &#177; 40.4 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.7 &#177; 35.3 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4 &#177; 1.0 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 &#177; 0.8 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3 &#177; 1.5 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3 &#177; 1.2 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;96% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;96% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;96% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;96% *</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NAT-T (ng/24 h)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">480.4 &#177; 292.0 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">377.0 &#177; 226.9 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.0 &#177; 2.5 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.2 &#177; 2.1 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 &#177; 3.7 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 &#177; 3.1 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98% *</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NNAL-T (ng/24 h) </td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">465.3 &#177; 249.1 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">475.3 &#177; 263.9 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132.7 &#177; 85.7 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135.8 &#177; 84.7 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.5 &#177; 47.7 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.3 &#177; 54.4 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;71% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;71% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;82% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;83% *</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Blood Biomarkers</bold>
</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood CoHB (%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.7 &#177; 1.2 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8 &#177; 1.3 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 &#177; 0.4 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 &#177; 0.3 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 &#177; 0.3 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 &#177; 0.3 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;62% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;66% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;61% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;65% *</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Plasma Nicotine ** (ng/mL)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.2 &#177; 6.5 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6 &#177; 5.1 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 &#177; 0.0 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 &#177; 0.0 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 &#177; 0.0 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 &#177; 0.0 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;98%</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Plasma Cotinine (ng/mL)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">236.6 &#177; 118.9 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">234.2 &#177; 112.7 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.9 &#177; 6.7 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1 &#177; 3.0 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6 &#177; 0.4 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 &#177; 0.1 (36)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;99% *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;100% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;100% *</td></tr></tbody></table><table-wrap-foot><fn><p>Percent change = (daily mean &#8722; baseline mean)/baseline mean &#215; 100, where baseline is Day &#8722;1. * Statistical significance of the mean difference from baseline (<italic toggle="yes">p</italic> &lt; 0.05). ** Statistical analysis could not be performed for plasma nicotine as all of the Day 7 and Day 14 data were reported as being below the limit of quantitation. Abbreviations: CEMA: 2-cyanoethylmercapturic acid; CoHB: carboxyhemoglobin; mg: milligram; mL: milliliter; n: sample size; NAB-T: Total N&#8217;-nitrosoanabasine; NAT-T: Total N&#8217;-nitrosoanatabine; NicEq-T: Total nicotine equivalents; ng: nanogram; NNAL-T: Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNN-T: Total N&#8217;-nitrosonornicotine; pg: picogram; SD: standard deviation; &#181;g: microgram.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-06286-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06286-t003_Table 3</object-id><label>Table 3</label><caption><p>Hematological BoPH changes upon smoking abstinence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hematological Biomarkers</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age Cohort</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomarker (Units)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Statistics</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time Point</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#8211;34 Years </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35&#8211;60 Years</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">White blood cells </td><td align="center" valign="middle" rowspan="1" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">7.83 &#177; 1.45 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.54 &#177; 2.82 (37)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(10<sup>9</sup>/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" rowspan="1" colspan="1">6.81 &#177; 1.38 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.41 &#177; 1.74 (37)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" rowspan="1" colspan="1">6.95 &#177; 1.46 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.71 &#177; 1.89 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Percent Change (<italic toggle="yes">p</italic>-value *)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;13% (&lt;0.0014)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;25% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;11% (0.0077)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;22% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils </td><td align="center" valign="middle" rowspan="1" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">4.72 &#177; 1.24 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.15 &#177; 2.27 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(10<sup>9</sup>/L) </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.87 &#177; 0.98 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.56 &#177; 1.33 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" rowspan="1" colspan="1">3.93 &#177; 0.93 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.71 &#177; 1.46 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Percent Change (<italic toggle="yes">p</italic>-value *)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;18% (&lt;0.0001)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;31% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;17% (0.0004)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;28% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes </td><td align="center" valign="middle" rowspan="1" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.23 &#177; 0.63 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.49 &#177; 0.67 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(10<sup>9</sup>/L) </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.13 &#177; 0.51 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.09 &#177; 0.6 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" rowspan="1" colspan="1">2.20 &#177; 0.61 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.23 &#177; 0.53 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Percent Change (<italic toggle="yes">p</italic>-value *)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;5% (0.1201)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;16% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1% (0.6331)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;11% (0.003)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Red blood cells </td><td align="center" valign="middle" rowspan="1" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.23 &#177; 0.37 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.87 &#177; 0.43 (37)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(10<sup>12</sup>/L) </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.11 &#177; 0.48 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.75 &#177; 0.50 (37)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" rowspan="1" colspan="1">5.04 &#177; 0.41 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.65 &#177; 0.52 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Percent Change (<italic toggle="yes">p</italic>-value *)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2% (0.0147)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;3% (0.0038)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;4% (&lt;0.0001)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;5% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">46.91 &#177; 2.68 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.02 &#177; 3.56 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" rowspan="1" colspan="1">45.75 &#177; 3.39 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.79 &#177; 3.97 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" rowspan="1" colspan="1">45.07 &#177; 3.04 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.12 &#177; 4.29 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Percent Change (<italic toggle="yes">p</italic>-value *)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2% (0.0163)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;3% (0.0007)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;4% (&lt;0.0001)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;4% (&lt;0.0001)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day &#8722;2</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">15.80 &#177; 0.96 (32)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">14.66 &#177; 1.41 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7</td><td align="center" valign="middle" rowspan="1" colspan="1">15.39 &#177; 1.11 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.21 &#177; 1.48 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" rowspan="1" colspan="1">15.20&#177; 1.06 (32)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.01 &#177; 1.57 (36)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Percent Change (<italic toggle="yes">p</italic>-value *)</td><td align="center" valign="middle" rowspan="1" colspan="1">Day 7 vs. Day &#8722;2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;3% (0.0117)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;3% (0.0003)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;4% (&lt;0.0001)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;4% (&lt;0.0001)</td></tr></tbody></table><table-wrap-foot><fn><p>* The <italic toggle="yes">p</italic>-value indicates the statistical significance of the comparison between original measurements.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-06286-t004" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06286-t004_Table 4</object-id><label>Table 4</label><caption><p>Changes in arterial blood gases and exhaled nitric oxide upon smoking abstinence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Physiological Biomarkers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age Cohort</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomarker (Units)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Statistics</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time Point</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#8211;34 Years</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35&#8211;60 Years</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PAO<sub>2</sub> (mmHg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.65 &#177; 9.26 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.51 &#177; 11.02 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.00 &#177; 10.02 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.13 &#177; 8.17 (36)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4% *</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PACO<sub>2</sub> (mmHg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.13 &#177; 3.28 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.95 &#177; 3.1 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.41 &#177; 2.98 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.91 &#177; 3.51 (36)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3% *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5% *</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">O<sub>2</sub> Saturation (%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.71 &#177; 0.85 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.67 &#177; 1.68 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.68 &#177; 1.3 (32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.38 &#177; 1.10 (36)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0% </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1% *</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bicarbonate (mmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.75 &#177; 1.87 (32) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.44 &#177; 1.76 (37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.38 &#177; 1.75 (32) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.28 &#177; 1.94 (36)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3% * </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4% *</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FeNO (ppb)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean &#177; SD (<italic toggle="yes">n</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.29 &#177; 9.07 (31) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.03 &#177; 19.56 (33)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.13 &#177; 18.42 (31) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.71 &#177; 10.78 (35)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 14 vs. Day &#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56% * </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5%</td></tr></tbody></table><table-wrap-foot><fn><p>Percent change = (daily mean &#8722; baseline mean)/baseline mean &#215; 100, where baseline is Day &#8722;1. * Statistical significance of the mean difference from baseline (<italic toggle="yes">p</italic> &lt; 0.05). FeNO = fractional exhaled expiratory nitric oxide; O<sub>2</sub> = oxygen; PAO<sub>2</sub> = partial pressure oxygen; PACO<sub>2</sub> = partial pressure carbon dioxide; ppb = parts per billion.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>